CH BIOTECH SER (08037) announced that on December 17, 2024, the company entered into a subscription agreement with the subscriber Guoyuan Securities Investment (Hong Kong), which conditionally agreed to subscribe for Convertible Bonds with a principal amount of 6 million USD (equivalent to approximately 46.68 million HKD).

According to the preliminary conversion price of 1.20 HKD (calculated at an Exchange Rates of 7.85 HKD to 1.00 USD), when the conversion rights attached to the Convertible Bonds are fully exercised, a maximum of 39.25 million shares of converted shares will be allocated and issued, equivalent to approximately 4.02% of the company's current issued share capital and approximately 3.87% of the issued share capital after expansion due to the issuance of converted shares.

The subscriber must pay the total subscription amount in a manner that offsets the existing convertible Bonds principal amount of 6 million US dollars on a one-to-one basis. Therefore, the company will not receive any cash proceeds from the subscription.

It is known that the subscriber is an indirect wholly-owned subsidiary of Guoyuan Securities Co., Ltd., which is incorporated in China and listed on the Shenzhen Stock Exchange (stock code: 000728.SZ). As of the date of this announcement, the subscriber is the holder of existing Convertible Bonds with an unpaid principal amount of 10 million USD, which can be converted into 54.1379 million shares at the conversion price of 1.45 HKD per share, equivalent to approximately 5.55% of the company's current issued share capital. The existing Convertible Bonds will be delivered and canceled upon completion.